Prostate cancer detection at repeat biopsy: Can pelvic phasedarray multiparametric MRI replace saturation biopsy?

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 1195-1200

  Pepe, Pietro ^a   Garufi, Antonio ^a   Priolo, Giandomenico ^a   Candiano, Giuseppe ^a   Pietropaolo, Francesco ^a   Pennisi, Michele ^a   Fraggetta, Filippo ^a   Aragona, Francesco ^a  

^a CANNIZZARO HOSPITAL   (Italy)

Author keywords

Multiparametric MRI; Pelvic phased array MRI; Prostate cancer; Saturation prostate biopsy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR BIOPSY;

AGED; BIOPSY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84875889213     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ and Auvinen A: Screening of prostate cancer mortality in randomized European study. N Engl Med 360: 1320-1328, 2009.
2. Pepe P and Aragona F: Prostate needle biopsy: 12 vs. 18 cores. Is it necessary? Urol Int 74: 19-22, 2005.
3. Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F, Shariat SF, Schroder FH and Scattoni V: Optimizing performance and interpretation of prostate biopsy: A critical analysis of the literature. Eur Urol 58: 851-864, 2010.
4. Pinkhasov GI, Lin YK, Palmerola R, Smith P, Mahon F, Kaag MG, Dagen JE, Harpster LE, Reese CT and Raman JD: Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases. BJU Int 110: 369-374, 2012.
5. Lawrentschuck N and Fleshner N: The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies elevated prostatic-specific antigen levels. BJU Int 103: 730-733, 2009.
6. Pinto PA, Chung PH, Rastinehad AR, Caccala AA Jr., Kruecker J and Bejamin CJ: Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 186: 1281-1285, 2011.
7. Franiel T, Stephan C, Erbersdobler A, Dietz E, Maxeiner A, Hell N, Huppertz A, Miller K, Strecker R and Hamm B: Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least on US-guided biopsy with a negative finding. Multiparametric MR imaging for detection and biopsy planning. Radiology 259: 162-172, 2011.
8. Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, Yakar D, van Oort IM, Witjes JA, Futterer JJ and Barentsz JO: Magnetic resonance imaging-guided prostate biopsy in men with repeat negative biopsies and increased prostate-specific antigen. J Urol 185: 520-527, 2010.
9. Kuru TH, Tulea C, Simpfendorfer T, Popeneciu V, Roethke M, Hadaschik BA and Hohenfellner M: MRI navigated stereotactic prostate biopsy: Fusion of MRI and real-time transrectal ultrasound images for perineal prostate biopsies. Urologe 51: 50-56, 2012.
10. Rosenkrantz AB, Mussi Mendrinos S, Babb JS and Taneja SS: Prostate cancer foci detected on multiparametric resonance imaging are distinct from those not detected. J Urol 187: 2032-2038, 2012.
11. Quentin M, Biondin D, Klasen J, Schek J, Buchbender C, Miese FR, Miese FR, Antoch G, Barski D, Albers P and Arsov C: Evaluation of a structured report of functional prostate magnetic resonance imaging in patients with suspicion for prostate cancer or under active surveillance. Urol Int 89: 25-29, 2012.
12. Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, Scheenen T, Futterer J, Bouwense S, van Oort I, Schroder F, Huisman H and Barentsz J: Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance image-guided biopsies versus systematic 10-core transrectal ultrasound prostate biopsy. Eur Urol 61: 177-184, 2012.
13. Turkbey B, Shah VP, Pang Y, Bernardo M, Xu S, Kruecker J, Locklin J, Baccala AA Jr, Rastinehad AR, Merino MJ, Shih JH, Wood BJ, Pinto PA and Choyke PL: Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MRI images? Radiology 258: 488-493, 2011.
14. Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, Khurana K, Ravizzini GC, Albert PS, Merino MJ and Choyke PL: Prostate cancer: Value of multiparametric MRI imaging at 3 T for detection-histopathologic correlation. Radiology 255: 89-94, 2010.
15. Arsov C, Quentin M, Rabenalt R, Antoch G, Albers P and Blondin D: Repeat transrectal ultrasound biopsies with additional targeted cores according to results of functional prostate MRI detects high-risk prostate cancer in patients with previous negative biopsy and increased PSA - a pilot study. Anticancer Res 32: 1087-1092, 2012.
16. Pepe P and Aragona F: Incidence of insignificant prostate cancer using free/total PSA: Results of a case-finding protocol on 14,453 patients. Prostate Cancer Prostatic Dis 13: 316-319, 2010.
17. Pepe P and Aragona F: Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 70: 1131-1135, 2007.
18. Mitterberger M, Horninger W, Pelzer A, Strasser H, Bartsch G, Moser P, Halpern EJ, Gradl J, Aigner F, Pallwein L and Frauscher F: A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: Impact on prostate cancer detection. Prostate 67: 1537-1542, 2007.
19. Pepe P, Panella P, Patane D and Aragona F: Does the adjunct of echographic contrast medium Levovist improve the detection rate of prostate cancer? Prostate Cancer Prostatic Dis 6: 159-162, 2003.
20. Pepe P, Candiano G, Pennisi M and Aragona F: Can Sonovue targeted biopsy replace extended or saturation biopsy in prostate cancer diagnosis? Our experience at primary and repeat biopsy. Archivio Italiano Urologia Andrologia 82: 155-159, 2010.
21. Turkbey B and Choyke PL: Multiparametric MRI and prostate cancer diagnosis and risk stratification. Curr Opin Urol 22: 310-315, 2012.
22. Epstein J, Walsh P and Carmichael M: Pathological and clinical findings to predict tumor extent of non palpable (stage T1c) prostate cancer. JAMA 271: 368-374, 1994.
23. Rud E, Baco E and Eggesbo HB: MRI and ultrasound-guided prostate biopsy using soft image fusion. Anticancer Res 32: 3383-3389, 2012.
24. Sonn GA, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ and Marks LS: Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol 189: 86-92, 2013.
25. Lecouvet FE, Mouedden JE and Collette L: Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace 99m Tc bone scanning and computed tomography for single-step detection of metastases in patients with high risk prostate cancer? Eur Urol 62: 68-75, 2012.